

## Authors:

Beom Joon Kim (Seoul National University Bundang Hospital)  
Sung-Chun Tang (National Taiwan University Hospital, Taipei, Taiwan)  
Yi-Chen Hsieh (Taipei Medical University)  
Chih-Hao Chen (National Taiwan University Hospital)  
Yong Soo Kim (Korea University Guro Hospital)  
Chun-Jen Lin (Taipei Veterans General Hospital)  
Jong-Moo Park (Uijeongbu Eulji Medical Center, Eulji University)  
Pi-Shan Sung (National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University)  
Kyunik Kang (Nowon Eulji Medical Center, Eulji University)  
Yu-Wei Chen (Landseed International Hospital)  
Soo Joo Lee (Eulji University Hospital)  
Kuan-Hung Lin (Chi Mei Medical Center)  
Jae-Kwan Cha (Dong-A University Hospital)  
Chih-Wei Tang (Far Eastern Memorial Hospital)  
Tai Hwan Park (Seoul Medical Center)  
Hai Jui Chu (En Chu Kong Hospital, New Taipei City, Taiwan)  
Kyungbok Lee (Soonchunhyang University College of Medicine)  
Chuan-Hsiu Fu (National Taiwan University Hospital, Hsin-Chu Branch)  
Jun Lee (Yeungnam University Medical Center, Daegu, Republic of Korea)  
Chao-Liang Chou (Mackay Memorial Hospital)  
Keun-Sik Hong (Ilsan Paik Hospital, Inje University)  
Ching-Huang Lin (Kaohsiung Veterans General Hospital)  
Kyung-Ho Yu (Hallym University Sacred Heart Hospital)  
Cheng-Yu Wei (Chang Bing Show Chwan Memorial Hospital)  
Dong-Eog Kim (Dongguk University Ilsan Hospital)  
Shang-Yih Yen (Tri Service General Hospital, National Defense Medical Center)  
Joon-Tae Kim (Chonnam National University Hospital)  
Po-Lin Chen (Taichung Veterans General Hospital)  
Jay Chol Choi (Jeju National University)  
Lung Chan (Stroke Center, Department of Neurology, Shuang Ho Hospital, College of Medicine, Taipei Medical University, New Taipei, Taiwan)  
Jee-Hyun Kwon (Ulsan university college of medicine)  
Dong-Ick Shin (Chungbuk National University Hospital)  
Sung-Il Sohn (Dongsan Hospital, Keimyung University School of Medicine)  
Hung-Yi Chiou (Taipei Medical University)  
Chulho Kim (Hallym University College of Medicine)  
Kwang-Yeol Park (Chung-Ang University College of Medicine, Chung-Ang University Hospital)  
Chi Kyung Kim (Korea University Guro Hospital and Korea University College of Medicine)  
Li-Ming Lien (Shin Kong Wu Ho-Su Memorial Hospital)  
Sung Hyuk Heo (Kyung Hee University Medical Center)  
Junn-Tay Lee (Tri-Service General Hospital, National Defense Medical Center)  
Hee-Joon Bae (Seoul National University Bundang Hospital)  
Jiann-Shing Jeng (National Taiwan University Hospital)

## Title Page

# Association Between Age And Endovascular Treatment Outcomes: Binational Registry Of 9941 EVT Cases From Korea And Taiwan

## Authors

Beom Joon Kim, MD, PhD<sup>1\*</sup>, Sung-Chun Tang, MD, PhD<sup>2\*</sup>, Yi-Chen Hsieh, PhD<sup>3</sup>, Chih-Hao Chen, MD, PhD<sup>2</sup>, Yong Soo Kim, MD<sup>1</sup>, Chun-Jen Lin, MD, PhD<sup>4</sup>, Jong-Moo Park, MD, PhD<sup>5</sup>, Pi-Shan Sung, MD, PhD<sup>6</sup>, Kyusik Kang, MD, PhD<sup>7</sup>, Yu-Wei Chen, MD, PhD<sup>8</sup>, Soo Joo Lee, MD, PhD<sup>9</sup>, Kuan-Hung Lin, MD<sup>10</sup>, Jae-Kwan Cha, MD, PhD<sup>11</sup>, Chih-Wei Tang, MD, PhD<sup>12</sup>, Tai Hwan Park, MD, PhD<sup>13</sup>, Hai-Jui Chu, MD<sup>14</sup>, Kyungbok Lee, MD, PhD<sup>15</sup>, Chuan-Hsiu Fu, MD<sup>16</sup>, Jun Lee, MD, PhD<sup>17</sup>, Chao-Liang Chou, MD<sup>18</sup>, Keun-Sik Hong, MD, PhD<sup>19</sup>, Ching-Huang Lin, MD, PhD<sup>20</sup>, Kyung-Ho Yu, MD, PhD<sup>21</sup>, Cheng-Yu Wei, MD<sup>22</sup>, Dong-Eog Kim, MD, PhD<sup>23</sup>, Shang-Yih Yen, MD<sup>24</sup>, Joon-Tae Kim, MD, PhD<sup>25</sup>, Po-Lin Chen, MD<sup>26</sup>, Jay Chol Choi, MD, PhD<sup>27</sup>, Lung Chan, MD, PhD<sup>28</sup>, Jee Hyun Kwon, MD, PhD<sup>29</sup>, Dong-Ick Shin, MD, PhD<sup>30</sup>, Sung-Il Sohn, MD, PhD<sup>31</sup>, Hung-Yi Chiou, PhD<sup>32</sup>, Chulho Kim, MD, PhD<sup>33</sup>, Kwang-Yeol Park, MD, PhD<sup>34</sup>, Chi Kyung Kim, MD, PhD<sup>35</sup>, Li-Ming Lien, MD, PhD<sup>36</sup>, Sung Hyuk Heo, MD, PhD<sup>37</sup>, Jiunn-Tay Lee, MD<sup>38</sup>, Hee-Joon Bae, MD, PhD<sup>1,39†</sup> and Jiann-Shing Jeng, MD, PhD<sup>2†</sup>

\* These authors contributed equally to this work.

† These authors contributed equally to this work as co-corresponding authors.

## Affiliations

1. Department of Neurology, Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Republic of Korea
2. Department of Neurology, National Taiwan University Hospital, Taiwan.
3. Program in Medical Neuroscience, Taipei Medical University, Taiwan.
4. Department of Neurology, Neurological Institute, Taipei Veterans General Hospital, Taiwan
5. Department of Neurology, Uijeongbu Eulji Medical center, Eulji University, Uijenongbu, Korea
6. Department of Neurology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan

7. Department of Neurology, Nowon Eulji Medical Center, Eulji University School of Medicine, Seoul, Korea
8. Department of Neurology, Landseed International Hospital, Taoyuan, Taiwan
9. Department of Neurology, Eulji University, School of Medicine, Daejeon Eulji Medical Center, Daejeon, Korea
10. Department of Neurology, Chi Mei Medical Center, Tainan, Taiwan
11. Department of Neurology, Dong-A University Hospital, Busan, Korea
12. Department of Neurology, Far Eastern Memorial Hospital, New Taipei City, Taiwan
13. Department of Neurology, Seoul Medical Center, Seoul, Korea
14. Department of Neurology, En Chu Kong Hospital, New Taipei City, Taiwan
15. Department of Neurology, Soonchunhyang University Seoul Hospital, Seoul, Korea
16. Department of Neurology, National Taiwan University Hospital Hsin-Chu Branch, Hsinchu City
17. Department of Neurology, Yeungnam University Medical Center, Daegu, Korea
18. Department of Neurology, Mackay Memorial Hospital, Taipei, Taiwan
19. Department of Neurology, Inje University Ilsan Paik Hospital, Goyang, Korea
20. Department of Neurology, Kaohsiung Veterans General Hospital, Taiwan
21. Department of Neurology, Hallym University Sacred Heart Hospital, Anyang, Korea
22. Department of Neurology, Chang Bing Show Chwan Memorial Hospital, Changhwa County, Taiwan
23. Department of Neurology, Dongguk University Ilsan Hospital, Goyang, Korea
24. Department of Neurology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan
25. Department of Neurology, Chonnam National University Medical School, Chonnam National University Hospital, Gwangju, Korea
26. Department of Neurology, Taichung Veterans General Hospital, Taiwan
27. Department of Neurology, Jeju National University Hospital, Jeju, Korea
28. Department of Neurology, Taipei Medical University-Shuang Ho Hospital, New Taipei City, Taiwan
29. Department of Neurology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea
30. Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju, Korea
31. Department of Neurology, Keimyung University Dongsan hospital, Keimyung University School of Medicine, Daegu, Korea
32. School of Public Health, College of Public Health, Taipei Medical University, Taiwan

33. Department of Neurology, Hallym University Chuncheon Sacred Heart Hospital, Gangwon-do, Korea
34. Department of Neurology, Chung-Ang University Hospital, Seoul, Korea
35. Department of Neurology, Korea University College of Medicine, Seoul, Korea.;  
Department of Neurology, Korea University Guro Hospital, Seoul, Korea
36. Department of Neurology, Shin Kong WHS Memorial Hospital, Taipei, Taiwan
37. Department of Neurology, Kyung Hee University Hospital, Seoul, Korea
38. Department of Neurology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan
39. Department of Neuroscience, College of Medicine, Seoul National University, Seoul, Republic of Korea

Count of items:

Word count of main text: 2031

Tables: 4

Figures: 2

*Correspondence to;*

Hee-Joon Bae, MD, PhD

Department of Neurology, Seoul National University Bundang Hospital,  
Seongnam-si, Gyeonggi-do, Republic of Korea

E-mail: [braindoc@snu.ac.kr](mailto:braindoc@snu.ac.kr)

Jlann-Shing Jeng, MD, PhD

Department of Neurology, National Taiwan University Hospital, Taipei, Taiwan.

E-mail: [jsjeng@ntu.edu.tw](mailto:jsjeng@ntu.edu.tw)

## Abstract

**Background and Purpose:** As populations age, there is an increasing need to optimize endovascular treatment (EVT) for acute ischemic stroke. We harmonized prospective stroke registries from Korea and Taiwan to enable direct comparisons of patient characteristics and clinical outcomes, with a particular focus on the impact of advanced age.

**Methods:** Prospective stroke registries in South Korea (CRCS-K) and Taiwan (TREAT-AIS) were harmonized to form a unified dataset of patients treated with EVT. EVT outcomes included 3-month modified Rankin Scale (mRS), symptomatic intracranial hemorrhage (SICH), and successful recanalization. We assessed the association between age and outcomes in the overall population and in those aged  $\geq 80$  years, adjusting for relevant covariates.

**Results:** A total of 9941 EVT cases (7835 from Korea and 2106 from Taiwan) were included. Patients had a mean age of  $70.1 \pm 12.9$  years (57.6% male, median NIHSS: 14 [IQR: 9–19]). Compared to Korean patients, Taiwanese patients had a higher prevalence of vascular risk factors and more severe strokes, contributing to lower rates of favorable 3-month outcomes. Increasing age was associated with poorer EVT results; among patients  $\geq 80$  years, only 18% achieved mRS 0–2, compared to 47% of younger patients. However, the risk of SICH did not significantly increase with age (adjusted OR per year: 1.00 [0.99–1.01]; adjusted OR  $\geq 80$  years: 1.05 [0.85–1.29]). Pre-stroke functional independence and bridging thrombolysis were identified as key modifiers of better outcomes even in the oldest patients.

**Conclusion:** Taiwanese EVT patients had more risk factors and worse outcomes than Korean patients. Advanced age is associated with poorer functional recovery, yet selected older patients—particularly those who were functionally independent before the stroke or received bridging thrombolysis—demonstrated meaningful benefit. These results underscore the importance of individualized treatment strategies and careful patient selection, especially as populations continue to age.

## Introduction

Timely recanalization is a key determinant of improved outcomes for patients with acute ischemic stroke (AIS).<sup>1</sup> Robust evidence from multiple randomized trials (RCTs) supports the safety and efficacy of recanalization therapies. In particular, a meta-analysis of five early RCTs revealed that endovascular thrombectomy (EVT) for large vessel occlusion (LVO) reduced disability by a factor of 2.5 compared to standard medical care.<sup>2</sup> As a result, rapid recanalization strategies – including intravenous thrombolysis and endovascular recanalization – have become integral to AIS management and are now widely adopted in clinical practice.

However, the clinical characteristics and etiologies of AIS differ significantly across ethnic groups. East Asian populations, including those in Korea, Taiwan, China, and Japan, constitute roughly 20% of the global population.<sup>3</sup> Yet, these groups remain underrepresented in high quality EVT trials.<sup>4</sup> Notably, patients in East Asia demonstrate a higher incidence of LVO driven by intracranial atherosclerosis (ICAS),<sup>5</sup> complicating endovascular navigation and increasing the technical complexity of procedures like suction thrombectomy. East Asian patients also have a higher prevalence of hemorrhagic complications post-reperfusion.<sup>6</sup> These ethnic and regional differences highlight the need for multinational, multicenter registries that focus on specific subpopulations, such as East Asians, to enhance the relevance and generalizability of EVT research.

While advanced age is a well-recognized risk factor for worse outcomes following EVT,<sup>7,8</sup> the concept of age-related treatment nihilism is unwarranted. Even elderly patients can benefit from EVT, provided that factors like brain frailty, premonitory functional status, and expected clinical outcomes are carefully considered.<sup>9</sup> As global population age, the incidence of AIS in older adults is expected to rise, making it imperative to understand how age influence EVT outcomes and to develop tailored strategies for older patients.

In this context, researchers in Taiwan and South Korea have established prospective stroke registries – TREAT-AIS in Taiwan and CRCS-K in Korea – to capture real-world EVT practices.<sup>10,11</sup> To advance understanding of country-specific differences in EVT outcomes across East Asia, these two groups aligned their datasets to form the K-T collaborative EVT registry. In this paper, we describe the organization structure and patient characteristics of this unified registry. Given the rapid aging of both population, we further explore the impact of age on EVT outcomes, providing insights that may guide clinical decision-making in real-world practice.

## Methods

### *Establishment and Operation of the K-T Collaborative EVT Registry*

The K-T collaborative EVT registry integrates patients-level data from the Clinical Research Collaboration for Stroke in Korea (CRCS-K) and the Taiwan Registry of Endovascular Thrombectomy for Acute Ischemic Stroke (TREAT-AIS), resulting in a harmonized, analyzable dataset. CRCS-K registry, initiated in 2008 and expanding into a broader coverage with prospective collection of stroke outcomes in 2011, had enrolled over 100,000 acute stroke admissions by December 2023.<sup>11</sup> It includes approximately 700 data elements capturing patient demographics, hyperacute treatment details, time metrics, stroke subtypes, in-hospital management, medications, and event and functional outcomes at 3 months and 1 year. TREAT-AIS, launched in January 2019 with contributions from 10 medical centers and 9 community hospitals in Taiwan, focuses on patients over 20 years old with AIS treated by EVT.<sup>10</sup> It records stroke severity, arterial occlusion location, recanalization strategies, and 3-month functional recovery.

In mid-2023, researchers from Korea and Taiwan convened in Taipei and agreed to harmonize these registries. For this study, CRCS-K contributed 7835 EVT-treated patients from January 1, 2011 to April 30, 2023, while TREAT-AIS provided 2106 EVT-treated patients enrolled up to April 30, 2023 (Supplemental Table 1). Data dictionaries and coding schemas from both registries were systematically reviewed to identify harmonizable fields. A biostatistician-led team, chaired by Hsieh Y-C, performed data harmonization, culminating in a unified dataset of 9941 EVT patients (7835 from Korea and 2106 from Taiwan) with roughly 200 common data fields.

Ethical approval for analyses was obtained from the Institutional Review Board of the Seoul National University Bundang Hospital (Approval ID, B-2410-928-104). The data that support the findings of this study are available from the corresponding author upon reasonable request.

### *Data Collection*

Researchers from both countries collaboratively reviewed the source registries' data dictionaries to identify common variables. These harmonized fields included baseline demographics, pre-stroke functional status, vascular risk factors, use of antithrombotics, stroke subtypes, baseline National Institutes of Health Stroke Scale (NIHSS) scores, LVO location, and key time metrics. The primary EVT outcomes encompassed symptomatic intracerebral hemorrhage (ICH), successful recanalization (modified



Thrombolysis in Cerebral Infarction [mTICI] score of 2b–3), 90-day modified Rankin Scale (mRS) scores, and 90-day mortality. Symptomatic ICH was defined as a type 2 parenchymal hematoma on neuroimaging obtained within 24–36 hours post-EVT, accompanied by a  $\geq 4$ -point increase in the NIHSS.

### *Statistical Analyses*

We first summarized baseline clinical characteristics and then investigated the association between age and EVT outcomes. Categorical variables were compared using chi-squared tests, parametric variables with independent t-tests, and non-parametric data with median tests. Multivariable logistic regression models, adjusted for clinically relevant covariates, were used to identify independent predictors of outcomes. Non-linearity was examined using restricted cubic splines. A two-tailed P-value  $< 0.05$  was considered significant. As this was an exploratory analysis, no corrections for multiple comparisons were applied.<sup>12</sup> All statistical analyses were performed using R version 4.4.1.

## **Results**

### *Baseline Characteristics and Comparison Between the Two Countries*

The K-T collaborative EVT registry comprised 9,941 cases: 7,835 from South Korea (CRCS-K) and 2,106 from Taiwan (TREAT-AIS). As shown in Table 1, the Taiwanese cohort was older on average ( $71.2 \pm 13.3$  vs.  $69.8 \pm 12.8$  years;  $P < 0.01$ ) and exhibited a higher prevalence of vascular risk factors including hypertension (73.4% vs. 62.9%), diabetes (34.3% vs. 28.6%), dyslipidemia (51.4% vs. 27.3%), and atrial fibrillation (52.9% vs. 46.6%), while smoking history was more common in the Korean cohort (32.7% vs. 28.1%). TREAT-AIS patients also had lower mean glomerular filtration rates ( $62.3 \pm 31.0$  vs.  $69.1 \pm 32.3$ ) and presented with more severe strokes (median NIHSS: 18 [13–23] vs. 14 [9–18]). Pre-stroke functional independence was less frequent in the Taiwanese group (71.9% vs. 80.5%).

Treatment timelines and patterns varied. Time from last known well to ER arrival was slightly longer in TREAT-AIS (medians [interquartile ranges]; 2.78 [1.03 – 5.38] vs. 2.62 [1.02 – 6.53] hours), resulting in lower IV thrombolysis rates (35.9% vs. 45.2%). Similarly, arrival-to-groin puncture times differed between cohorts (2.40 [1.77–3.37] hours in TREAT-AIS vs. 1.72 [1.32–2.30] hours in CRCS-K).



### *Prognostic Factors for Outcomes After Endovascular Recanalization Treatment*

Successful recanalization rates were similar (84.0% vs. 80.0%), as were symptomatic hemorrhagic transformation rates (5.2% vs. 7.9%). However, functional independence at 90 days was less common in TREAT-AIS (34.7% vs. 41.1%), while 90-day mortality was higher in CRCS-K (14.2% vs. 6.2%). Multivariable logistic regression identified key predictors of outcomes (Supplemental Table 2). Age, pre-stroke functional independence, baseline NIHSS, diabetes, initial hemoglobin, glucose, blood urea nitrogen levels, posterior circulation occlusion, and bridging thrombolysis were each associated with functional recovery and mortality. For SICH, age, pre-stroke independence, baseline NIHSS, anterior circulation occlusion, and platelet and glucose levels, while age, sex, pre-stroke independence, and stroke subtype predicted successful recanalization.

### *Detailed Analyses of Age as a Prognosticator After EVT*

The mean age of EVT-treated patients was  $70.1 \pm 12.9$  years (range: 7–103). Of these, 24.9% were  $\geq 80$  years old, and 3.0% were  $\geq 90$  years old. (Supplemental Figure 1). Elderly patients ( $\geq 80$  years) were more likely to be from Taiwan, were less frequently male, and less often functionally independent prior to stroke. They had more severe neurological deficits at presentation, arrived later, and were less likely to receive IV thrombolysis (34.6% vs. 46.1%). Compared to younger counterparts, older patients had lower rates of favorable functional outcomes (18.1% vs. 46.9%), higher mortality (19.7% vs. 10.5%; Figure 1), and lower successful recanalization rates (78.6% vs. 81.9%; Table 2, Supplemental Table 3).

Multivariable modeling underscored the influence of age on outcomes, with adjusted ORs of 0.35 [0.30–0.40] for mRS 0–2, 1.49 [1.25–1.76] for mortality, and 0.75 [0.64–0.87] for TICl 2b–3. In contrast, the incidence of SICH was comparable across age groups (7.1% vs. 7.3%, OR: 1.04 [0.84–1.28]; Table 3). Age exhibited a nonlinear relationship with functional recovery and mortality, most pronounced between 75–85 years (Figure 2; OR per 1-year increase for mRS 0–2: 0.90 [0.87–0.93]; OR for mortality: 1.05 [1.01–1.10]), while its relationship with SICH and successful recanalization appeared more linear (Supplemental Table 4). Stratified analyses consistently identified pre-stroke independence and baseline NIHSS as key modifiers of outcomes across all ages, while baseline glucose and cardioembolic stroke etiology remained influential for SICH and recanalization, respectively (Supplemental Tables 5–8).

In patients  $\geq 80$  years, favorable recovery was predicted by younger age within this subgroup, female sex, pre-stroke independence, lower baseline NIHSS, and

bridging thrombolysis. Mortality predictors included pre-stroke independence, pre-EVT tPA use, initial hemoglobin, eGFR, and bridging thrombolysis (Table 4).

## Discussion

By integrating two national stroke registries from Korea and Taiwan, we created a harmonized dataset of 9,941 EVT-treated patients. Our analyses revealed that Taiwanese patients tended to have more complex vascular risk profiles and more severe neurological deficits, correlating with lower rates of functional recovery. We also confirmed that age strongly influences EVT outcomes, particularly between 75 and 85 years. Notably, however, the risk of symptomatic hemorrhagic transformation did not differ significantly by age.

This multinational registry provides unique insights into EVT performance in East Asia. While major RCTs have firmly established EVT's efficacy,<sup>13</sup> challenges remain in translating these findings to diverse populations and in optimizing patient selection.<sup>14</sup> The inclusion of patients who may be underrepresented in clinical trials—such as the very elderly or those with extensive comorbidities and East Asians—enables a more nuanced understanding of EVT's real-world impact and supports more individualized treatment approaches.

Our results highlight how differences in baseline demographics, risk factors, and care pathways between Taiwan and Korea can shape EVT outcomes. Multinational datasets are instrumental for identifying such variations, informing clinicians, and guiding policymakers to refine care models.<sup>15</sup> More granular insights into factors like stroke subtype, bridging therapies, comorbidities and baseline imaging can help tailor EVT strategies to different healthcare contexts and population needs.

Consistent with previous studies, we found that advanced age often portends worse functional recovery and higher mortality.<sup>7,8</sup> In our dataset, patients aged 80 and older had significantly worse outcomes compared to younger patients, with lower rates of functional independence (10.8% vs. 32.3%) and higher mortality (19.7% vs. 10.5%). These results align with previous studies that identified age as a significant predictor of poor outcomes and futile revascularization after EVT.<sup>16,17</sup> When compared to a post-hoc analysis of HERMES collaboration,  $\geq 80$  year-old patients from Korea and Taiwan achieved comparable functional recovery with higher mortality and SICH.<sup>18</sup>

Several factors likely contribute to the worse outcomes observed in older patients. Older patients tend to have a higher burden of comorbidities, more severe strokes at presentation, and delayed treatment initiation, all of which compromise functional

gains.<sup>19,20</sup> Yet, our findings, consistent with previous studies, do not support an age-based exclusion from EVT.<sup>21,22</sup> Even among the elderly, approximately 16% achieved favorable outcomes. Moreover, pre-stroke functional independence and the use of bridging IV thrombolysis were strong predictors of improved outcomes in the elderly. This underscores the importance of considering factors beyond chronological age—such as ischemic core and penumbra volumes, stroke location, comorbidities, frailty, and bridging thrombolysis—in patient selection.<sup>23</sup>

The strengths of our study lie in its large scale, multinational design, and prospective data collection. By analyzing a broad range of clinical profiles, we offer insights that may be more generalizable than single-country or strictly trial-based data.<sup>24</sup> Nonetheless, this analysis has limitations. Differences in data collection methods and definitions between registries may affect comparability. The inclusion periods vary by registry, and detailed imaging data or post-discharge care information were not available. Such factors, along with the retrospective nature of these analyses, warrant cautious interpretation.

In conclusion, our multinational approach demonstrates the value of harmonizing stroke registries to advance global stroke care. We show that while advanced age is associated with poorer EVT outcomes, carefully selected elderly patients can still derive meaningful benefit. Future collaborative efforts should focus on refining EVT techniques, integrating imaging and longitudinal follow-up data, and systematically addressing regional variations in care delivery. Such endeavors will ultimately improve EVT strategies and outcomes across East Asia, ensuring that an ever-widening population of patients receives the most effective acute stroke interventions.

## Acknowledgement

A complete list of participating researchers is provided as an Appendix in the Supplemental Data.

### *Source of Funding*

This research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute, funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HI22C0454).

### *Disclosures*

The authors declare no competing interests regarding the acquisition of data, analysis, reporting of results, and publication.

## References

1. Saver JL, Goyal M, van der Lugt A, Menon BK, Majoie CB, Dippel DW, Campbell BC, Nogueira RG, Demchuk AM, Tomasello A, et al. Time to Treatment With Endovascular Thrombectomy and Outcomes From Ischemic Stroke: A Meta-analysis. *JAMA*. 2016;316:1279-1288. doi: 10.1001/jama.2016.13647
2. Goyal M, Menon BK, van Zwam WH, Dippel DW, Mitchell PJ, Demchuk AM, Davalos A, Majoie CB, van der Lugt A, de Miquel MA, et al. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. *Lancet*. 2016;387:1723-1731. doi: 10.1016/S0140-6736(16)00163-X
3. Eastern Asia Population. <https://www.worldometers.info/world-population/eastern-asia-population>. Accessed October 1, 2024.
4. Acton EK, Abbasi MH, Kasner SE. Evaluating Age, Sex, Racial, and Ethnic Representation in Acute Ischemic Stroke Trials, 2010 to 2020: A Systematic Review and Meta-Analysis. *J Am Heart Assoc*. 2022;11:e024651. doi: 10.1161/JAHA.121.024651
5. Kim JS, Bonovich D. Research on intracranial atherosclerosis from the East and west: why are the results different? *J Stroke*. 2014;16:105-113. doi: 10.5853/jos.2014.16.3.105
6. Venketasubramanian N, Yoon BW, Pandian J, Navarro JC. Stroke Epidemiology in South, East, and South-East Asia: A Review. *J Stroke*. 2017;19:286-294. doi: 10.5853/jos.2017.00234
7. Groot AE, Treurniet KM, Jansen IGH, Lingsma HF, Hinsenveld W, van de Graaf RA, Roozenbeek B, Willems HC, Schonewille WJ, Marquering HA, et al. Endovascular treatment in older adults with acute ischemic stroke in the MR CLEAN Registry. *Neurology*. 2020;95:e131-e139. doi: 10.1212/WNL.00000000000009764
8. Proietti M, Mascolo AP, Maramma F, Morosetti D, Da Ros V, Gandini R, Alemseged F, Diomedi M, Koch G, Sallustio F. Impact of old and very old age on outcomes in patients with acute ischemic stroke undergoing endovascular therapy. *European Heart Journal*. 2020;41. doi: 10.1093/ehjci/ehaa946.3243
9. Ospel J, Kappelhof M, Groot AE, LeCouffe NE, Coutinho JM, Yoo AJ, Yo LSF, Beenen LFM, van Zwam WH, van der Lugt A, et al. Combined Effect of Age and Baseline Alberta Stroke Program Early Computed Tomography Score on Post-Thrombectomy Clinical Outcomes in the MR CLEAN Registry. *Stroke*. 2020;51:3742-3745. doi: 10.1161/STROKEAHA.120.031773
10. Tang SC, Hsieh YC, Lin CJ, Chen YW, Lin KH, Sung PS, Hsieh MT, Tang CW, Chu HJ, Tsai KC, et al. TREAT-AIS: A Multicenter National Registry. *Stroke: Vascular and Interventional Neurology*. 2023;3. doi: 10.1161/svin.123.000861
11. Kim BJ, Park JM, Kang K, Lee SJ, Ko Y, Kim JG, Cha JK, Kim DH, Nah HW, Han MK, et al. Case characteristics, hyperacute treatment, and outcome information from the clinical research center for stroke-fifth division registry in South Korea. *J Stroke*. 2015;17:38-53. doi: 10.5853/jos.2015.17.1.38

12. Rubin M. Do p Values Lose Their Meaning in Exploratory Analyses? It Depends How You Define the Familywise Error Rate. *Review of General Psychology*. 2017;21:269-275. doi: 10.1037/gpr0000123
13. Yaghi S, Siegler JE, Nguyen TN. Pitfalls of Randomized Controlled Trials in Stroke: How Can We Do Better? *Stroke: Vascular and Interventional Neurology*. 2023;3. doi: 10.1161/svin.123.000807
14. Ospel JM, Kashani N, Almekhlafi M, Chapot R, Goyal M. Influence of Age on EVT Treatment Decision in Patients with Low ASPECTS : Results of a Multinational Survey and its Implications. *Clin Neuroradiol*. 2020;30:37-40. doi: 10.1007/s00062-019-00872-3
15. Fasugba O, Sedani R, Mikulik R, Dale S, Varecha M, Coughlan K, McElduff B, McInnes E, Hladikova S, Cadilhac DA, et al. How registry data are used to inform activities for stroke care quality improvement across 55 countries: A cross-sectional survey of Registry of Stroke Care Quality (RES-Q) hospitals. *Eur J Neurol*. 2024;31:e16024. doi: 10.1111/ene.16024
16. Hassan AE, Chaudhry SA, Grigoryan M, Tekle WG, Qureshi AI. National trends in utilization and outcomes of endovascular treatment of acute ischemic stroke patients in the mechanical thrombectomy era. *Stroke*. 2012;43:3012-3017. doi: 10.1161/STROKEAHA.112.658781
17. Zhou T, Yi T, Li T, Zhu L, Li Y, Li Z, Wang M, Li Q, He Y, Yang P, et al. Predictors of futile recanalization in patients undergoing endovascular treatment in the DIRECT-MT trial. *J NeuroIntervent Surg*. 2022;14:752-755. doi: 10.1136/neurintsurg-2021-017765
18. McDonough RV, Ospel JM, Campbell BCV, Hill MD, Saver JL, Dippel DWJ, Demchuk AM, Majoie C, Brown SB, Mitchell PJ, et al. Functional Outcomes of Patients  $\geq$ 85 Years With Acute Ischemic Stroke Following EVT: A HERMES Substudy. *Stroke*. 2022;53:2220-2226. doi: 10.1161/STROKEAHA.121.037770
19. Kelly DM, Rothwell PM. Impact of multimorbidity on risk and outcome of stroke: Lessons from chronic kidney disease. *Int J Stroke*. 2021;16:758-770. doi: 10.1177/1747493020975250
20. Fonarow GC, Reeves MJ, Zhao X, Olson DM, Smith EE, Saver JL, Schwamm LH, Get With the Guidelines-Stroke Steering C, Investigators. Age-related differences in characteristics, performance measures, treatment trends, and outcomes in patients with ischemic stroke. *Circulation*. 2010;121:879-891. doi: 10.1161/CIRCULATIONAHA.109.892497
21. Winkelmeier L, Kniep H, Faizy T, Heitkamp C, Holtz L, Meyer L, Flottmann F, Heitkamp A, Schell M, Thomalla G, et al. Age and Functional Outcomes in Patients With Large Ischemic Stroke Receiving Endovascular Thrombectomy. *JAMA Netw Open*. 2024;7:e2426007. doi: 10.1001/jamanetworkopen.2024.26007
22. Rhiner N, Thut MZ, Thurner P, Madjidyar J, Schubert T, Globas C, Wegener S, Luft AR, Michels L, Kulcsar Z. Impact of age on mechanical thrombectomy and clinical outcome in patients with acute ischemic stroke. *J Stroke Cerebrovasc Dis*. 2023;32:107248. doi: 10.1016/j.jstrokecerebrovasdis.2023.107248
23. Tanaka K, Yamagami H, Qureshi MM, Uchida K, Siegler JE, Nogueira RG, Yoshimura S, Sakai N, Martinez-Majander N, Nagel S, et al. Endovascular

- Therapy in the Extended Time Window for Large Vessel Occlusion in Patients With Pre-Stroke Disability. *J Stroke*. 2024;26:269-279. doi: 10.5853/jos.2023.04259
24. Marzano L, Darwich AS, Dan A, Tendler S, Lewensohn R, De Petris L, Raghothama J, Meijer S. Exploring the discrepancies between clinical trials and real-world data: A small-cell lung cancer study. *Clin Transl Sci*. 2024;17:e13909. doi: 10.1111/cts.13909



## Figure Legends

Figure 1. Distribution of mRS scores at 3 months after stroke





Figure 2. Non-linear association between age and selected outcomes following endovascular treatment (EVT)

(A) Favorable functional recovery, defined as a modified Rankin Scale (mRS) score of 0-2 at 3 months, (B) Mortality within 3 months post-stroke, (C) Incidence of symptomatic intracerebral hemorrhage, and (D) Successful recanalization, defined as post-EVT TIC1 2b-3. These associations were modeled using restricted cubic spline curves (dark blue lines) with 95% confidence intervals (light blue shading).



## Tables

Table 1. Overall characteristics of endovascular treatment cases and comparison between South Korea (CRCS-K registry) and Taiwan (TREAT-AIS registry)

	Overall	South Korea	Taiwan	P-for-difference
Number of patients	9941	7835	2106	
Demographic information				
Male sex (%)	5727 (57.6)	4547 (58.0)	1180 ( 56.0)	0.104
age (mean (SD))	70.07 (12.92)	69.79 (12.78)	71.13 (13.38)	<0.001
Pre-stroke independence (%)	7331 (79.1)	6199 (80.5)	1132 ( 71.9)	<0.001
Stroke information				
LKW to arrival (hours; median [IQR])	2.62 [1.02, 6.38]	2.62 [1.02, 6.53]	2.78 [1.03, 5.38]	0.047
Unwitnessed onset (%)	3446 (41.6)	3183 (42.1)	263 ( 36.9)	0.008
initial NIHSS score (median [IQR])	14 [9- 19]	14 [9 - 18]	18 [13 - 23]	<0.001
Bridging thrombolysis (%)	4297 (43.2)	3540 (45.2)	757 ( 35.9)	<0.001
Arrival to IVT (hours; median [IQR])	0.60 [0.41, 0.83]	0.57 [0.40, 0.78]	0.80 [0.57, 1.00]	<0.001
Arrival to groin puncture (hours; median [IQR])	1.83 [1.37, 2.52]	1.72 [1.32, 2.30]	2.40 [1.77, 3.37]	<0.001
Ischemic stroke subtype				<0.001
Large artery atherosclerosis (%)	2738 (27.5)	2008 (25.6)	730 ( 34.7)	
Cardioembolism (%)	4734 (47.6)	3771 (48.1)	963 ( 45.7)	
Other-determined etiologies (%)	387 ( 3.9)	279 ( 3.6)	108 ( 5.1)	
Undetermined etiologies (%)	2082 (20.9)	1777 (22.7)	305 ( 14.5)	
Occlusion at posterior circulation (%)	1339 (13.5)	1090 (13.9)	249 ( 11.8)	0.014
Vascular risk factors				
Hypertension (%)	6472 (65.1)	4929 (62.9)	1543 ( 73.4)	<0.001
Diabetes (%)	2957 (29.8)	2237 (28.6)	720 ( 34.3)	<0.001
Dyslipidemia (%)	3213 (32.4)	2136 (27.3)	1077 ( 51.4)	<0.001
Current smoking (%)	3152 (31.7)	2561 (32.7)	591 ( 28.1)	<0.001
History of stroke (%)	1888 (19.0)	1473 (18.8)	415 ( 19.7)	0.348
Atrial fibrillation (%)	4763 (47.9)	3649 (46.6)	1114 ( 52.9)	<0.001
History of ischemic heart disease (%)	1247 (12.5)	943 (12.0)	304 ( 14.4)	0.004
History of heart failure (%)	351 ( 3.5)	150 ( 1.9)	201 ( 9.5)	<0.001
History of BP-lowering medication (%)	4932 (49.6)	3970 (50.7)	962 ( 45.7)	<0.001
History of glucose-lowering medication (%)	1960 (19.7)	1584 (20.2)	376 ( 17.9)	0.017
History of cholesterol-lowering medication (%)	704 ( 7.1)	321 ( 4.1)	383 ( 18.2)	<0.001

History of antiplatelets use (%)	2415 (24.3)	2023 (25.8)	392 ( 18.6)	<0.001
History of anticoagulants use (%)	1318 (13.3)	995 (12.7)	323 ( 15.3)	0.002
Concomitant cancer (%)	519 ( 7.3)	247 ( 4.9)	272 ( 12.9)	<0.001
Laboratory information				
Hemoglobin (g/dL; mean (SD))	13.4 (2.1)	13.4 (2.1)	13.4 (2.3)	0.375
Platelet count (x 10 <sup>3</sup> ; mean (SD))	216 (68)	217 (66)	213 (75)	0.01
PT INR (mean (SD))	1.09 (0.38)	1.08 (0.25)	1.11 (0.70)	0.001
Hemoglobin A1c (%; mean (SD))	6.2 (1.2)	6.1 (1.1)	6.3 (1.4)	<0.001
Glucose level on arrival (mg/dL; mean (SD))	142 (53)	141 (52)	146 (58)	<0.001
Blood urea nitrogen (mg/dL; mean (SD))	18.2 (9.0)	17.9 (8.0)	19.7 (12.4)	<0.001
Creatinine (mg/dL; mean (SD))	1.03 (0.81)	0.99 (0.70)	1.19 (1.12)	<0.001
Glucose level, fasting (mg/dL; mean (SD))	133 (51)	131 (50)	142 (55)	<0.001
Total cholesterol (mg/dL; mean (SD))	161 (42)	162 (42)	157 (42)	<0.001
estimated glomerular filtration rate (mean (SD))	67.7 (32.2)	69.1 (32.3)	62.3 (31.0)	<0.001
Treatment outcomes				
mRS score 0 - 1 at 3 months (%)	2421 (27.1)	2055 (28.2)	366 ( 22.2)	<0.001
mRS score 0 - 2 at 3 months (%)	3569 (40.0)	2996 (41.1)	573 ( 34.7)	<0.001
Mortality up to 3 months (%)	1138 (12.7)	1036 (14.2)	102 ( 6.2)	<0.001
Post-EVT TICl 2b-3 (%)	6562 (81.1)	4793 (80.0)	1769 ( 84.0)	<0.001
Symptomatic hemorrhage, post-EVT (%)	730 ( 7.3)	621 ( 7.9)	109 ( 5.2)	<0.001

P-values from the comparison between Korean and Taiwanese EVT cases

Table 2. Selected baseline characteristics comparing EVT patients with <80 year-old and ≥80 year-old

	<80 year-old	≥80 year-old	P-for-difference
Number of patients	7458	2477	
Taiwanese (%)	1471 (19.7)	629 (25.4)	<0.001
Demographic information			
Male sex (%)	4754 (63.7)	968 (39.1)	<0.001
age (mean (SD))	65.26 (11.14)	84.58 (3.89)	<0.001
Pre-stroke independence (%)	5890 (84.3)	1436 (63.0)	<0.001
Stroke information			
LKW to arrival (hours; median [IQR])	2.53 [1.00, 6.32]	2.88 [1.15, 6.63]	0.002
initial NIHSS score (median [IQR])	14.00 [9.00, 18.00]	16.00 [12.00, 21.00]	<0.001
Intravenous thrombolysis (%)	3437 (46.1)	856 (34.6)	<0.001
Arrival to IVT (hours; median [IQR])	0.60 [0.40, 0.82]	0.63 [0.42, 0.87]	0.019
Arrival to groin puncture (hours; median [IQR])	1.85 [1.38, 2.53]	1.80 [1.35, 2.51]	0.107
Ischemic stroke subtype			
Large artery atherosclerosis (%)	2222 (29.8)	514 (20.8)	
Cardioembolism (%)	3278 (44.0)	1453 (58.7)	
Other-determined etiologies (%)	351 ( 4.7)	35 ( 1.4)	
Undetermined etiologies (%)	1607 (21.5)	475 (19.2)	
Occlusion at posterior circulation (%)	998 (13.4)	341 (13.8)	0.651
Vascular risk factors			
Hypertension (%)	4567 (61.3)	1901 (76.7)	<0.001
Diabetes (%)	2201 (29.5)	755 (30.5)	0.368
Dyslipidemia (%)	2385 (32.0)	825 (33.4)	0.216
Current smoking (%)	2804 (37.6)	344 (13.9)	<0.001
Atrial fibrillation (%)	3182 (42.7)	1579 (63.7)	<0.001
Concomitant cancer (%)	371 ( 7.2)	147 ( 7.5)	0.711
Laboratory information			
Hemoglobin (g/dL; mean (SD))	13.65 (2.08)	12.60 (1.98)	<0.001
Hemoglobin A1c (%; mean (SD))	6.19 (1.24)	6.08 (0.95)	<0.001
Glucose level on arrival (mg/dL; mean (SD))	142.70 (54.94)	140.22 (48.57)	0.048
Blood urea nitrogen (mg/dL; mean (SD))	17.45 (8.48)	20.61 (9.98)	<0.001
Creatinine (mg/dL; mean (SD))	1.01 (0.84)	1.08 (0.73)	<0.001
estimated glomerular filtration rate (mean (SD))	75.48 (32.10)	44.18 (17.60)	<0.001
Treatment outcomes			

mRS score 0 - 1 at 3 months (%)	2183 (32.3)	235 (10.8)	<0.001
mRS score 0 - 2 at 3 months (%)	3170 (46.9)	394 (18.1)	<0.001
Mortality up to 3 months (%)	710 (10.5)	428 (19.7)	<0.001
Post-EVT TICl 2b-3 (%)	4870 (81.9)	1687 (78.6)	0.001
Symptomatic hemorrhage, post-EVT (%)	532 ( 7.1)	198 ( 8.0)	0.168

Table 3. Effect of age strata (< 80 versus ≥80 years old) on the EVT outcomes

Predictors	adjusted odds ratio	95% confidence interval
Dependent variable: favorable functional recovery (mRS score 0 - 2) at 3 months		
≥80 year-old	0.35	[ 0.30 – 0.40 ]
Male sex	1.05	[ 0.92 – 1.20 ]
Prestroke independence	1.91	[ 1.63 – 2.24 ]
Initial NIHSS score	0.89	[ 0.88 – 0.90 ]
Hypertension	0.86	[ 0.77 – 0.97 ]
Diabetes	0.79	[ 0.68 – 0.92 ]
Current smoking	1.14	[ 1.00 – 1.30 ]
History of stroke	0.87	[ 0.75 – 1.01 ]
History of heart failure	1.08	[ 0.96 – 1.21 ]
Hemoglobin	1.07	[ 1.04 – 1.10 ]
Hemoglobin A1c	0.97	[ 0.90 – 1.04 ]
Glucose level on arrival	0.996	[ 0.995 – 0.997 ]
Blood urea nitrogen	0.986	[ 0.979 – 0.993 ]
Total cholesterol	0.999	[ 0.998 – 1.000 ]
Occlusion at posterior circulation	0.84	[ 0.71 – 0.99 ]
Bridging thrombolysis	1.62	[ 1.45 – 1.82 ]
Dependent variable: mortality up to 3 months		
≥80 year-old	1.49	[ 1.25 – 1.76 ]
Male sex	1.27	[ 1.06 – 1.52 ]
Prestroke independence	0.62	[ 0.52 – 0.75 ]
Initial NIHSS score	1.09	[ 1.08 – 1.10 ]
Hypertension	1.08	[ 0.92 – 1.28 ]
Diabetes	1.07	[ 0.87 – 1.30 ]
Current smoking	0.90	[ 0.74 – 1.09 ]
History of stroke	0.95	[ 0.78 – 1.15 ]
History of heart failure	0.95	[ 0.81 – 1.12 ]
Hemoglobin	0.85	[ 0.82 – 0.89 ]
Hemoglobin A1c	1.01	[ 0.92 – 1.10 ]
Glucose level on arrival	1.004	[ 1.002 – 1.006 ]
Blood urea nitrogen	1.024	[ 1.016 – 1.031 ]
Total cholesterol	1.000	[ 0.998 – 1.002 ]
Occlusion at posterior circulation	1.58	[ 1.30 – 1.93 ]
Bridging thrombolysis	0.69	[ 0.58 – 0.80 ]
Dependent variable: Symptomatic hemorrhage		
≥80 year-old	1.05	[ 0.85 – 1.29 ]





Male sex	0.99	[ 0.83 – 1.19 ]
Prestroke independence	1.58	[ 1.24 – 2.02 ]
Initial NIHSS score	1.03	[ 1.01 – 1.04 ]
Diabetes	1.07	[ 0.85 – 1.35 ]
Atrial fibrillation	1.37	[ 1.14 – 1.64 ]
Platelet count	0.997	[ 0.996 – 0.999 ]
Hemoglobin A1c	0.94	[ 0.85 – 1.05 ]
Glucose level on arrival	1.006	[ 1.004 – 1.007 ]
Low density lipoprotein	1.000	[ 0.997 – 1.002 ]
Occlusion at posterior circulation	0.71	[ 0.54 – 0.93 ]
Bridging thrombolysis	0.99	[ 0.83 – 1.19 ]
Dependent variable: Successful recanalization		
≥80 year-old	0.75	[ 0.64 – 0.87 ]
Male sex	1.35	[ 1.18 – 1.54 ]
Prestroke independence	1.24	[ 1.06 – 1.45 ]
Initial NIHSS score	1.00	[ 0.99 – 1.01 ]
Atrial fibrillation	0.81	[ 0.67 – 0.99 ]
Glucose level on arrival	0.999	[ 0.998 – 1.001 ]
Total cholesterol	0.999	[ 0.997 – 1.000 ]
Stoke subtype		
Large artery atherosclerosis	reference	
Cardioembolism	2.68	[ 2.14 – 3.36 ]
Other-determined etiologies	1.36	[ 0.98 – 1.89 ]
Undetermined etiologies	1.89	[ 1.56 – 2.27 ]
Occlusion at posterior circulation	0.94	[ 0.79 – 1.13 ]
Bridging thrombolysis	1.12	[ 0.98 – 1.28 ]

Table 4. Prognostic factors for functional recovery and mortality after endovascular treatment in ≥80 year-old patients


Predictors	adjusted odds ratio	95% confidence interval
Dependent variable: favorable functional recovery (mRS score 0 - 2) at 3 months		
Age	0.93	[ 0.90 – 0.97 ]
Male sex	1.44	[ 1.10 – 1.90 ]
Prestroke independence	2.05	[ 1.51 – 2.78 ]
Initial NIHSS score	0.90	[ 0.88 – 0.92 ]
Diabetes	0.75	[ 0.55 – 1.03 ]
Current smoking	1.13	[ 0.79 – 1.61 ]
History of stroke	0.82	[ 0.59 – 1.14 ]
Hemoglobin	1.04	[ 0.97 – 1.11 ]
Initial glucose	0.998	[ 0.994 – 1.001 ]
Estimated GFR	0.997	[ 0.989 – 1.004 ]
Bridging thrombolysis	1.62	[ 1.24 – 2.10 ]
Dependent variable: mortality up to 3 months		
Age	1.04	[ 1.003 – 1.07 ]
Male sex	1.59	[ 1.24 – 2.05 ]
Prestroke independence	0.76	[ 0.59 – 0.97 ]
Initial NIHSS score	1.07	[ 1.05 – 1.09 ]
History of ischemic heart disease	1.27	[ 0.93 – 1.74 ]
History of heart failure	2.73	[ 1.56 – 4.79 ]
Hemoglobin	0.90	[ 0.84 – 0.95 ]
Prothrombin INR	1.48	[ 0.92 – 2.36 ]
Initial glucose	1.004	[ 1.002 – 1.006 ]
Estimated GFR	0.988	[ 0.980 – 0.996 ]
Posterior circulation occlusion	1.19	[ 0.86 – 1.65 ]
Bridging thrombolysis	0.74	[ 0.57 – 0.96 ]

# Distribution of mRS Scores at 3 months after stroke





# Distribution of mRS Scores at 3 months after stroke by Age Group

## less than 80 years old




medRxiv preprint doi: <https://doi.org/10.1101/2024.12.31.24319838>; this version posted January 3, 2025. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.


## equal to or greater than 80 years old




**Spline Curve for mRS 0 - 2 by age with 95% CI**



**Spline Curve for mortality at 3 months by age with 95% CI**



**Spline Curve for Symptomatic ICH By Age with 95% CI**



**Spline Curve for Successful Recanalization By Age with 95% CI**

